Mutual of America Capital Management LLC Sells 21,706 Shares of Vericel Co. (NASDAQ:VCEL)

Mutual of America Capital Management LLC lowered its stake in Vericel Co. (NASDAQ:VCEL - Free Report) by 13.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 145,448 shares of the biotechnology company's stock after selling 21,706 shares during the period. Mutual of America Capital Management LLC owned 0.30% of Vericel worth $5,179,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. DekaBank Deutsche Girozentrale purchased a new position in shares of Vericel during the fourth quarter worth $33,000. Tower Research Capital LLC TRC raised its holdings in shares of Vericel by 174.3% during the first quarter. Tower Research Capital LLC TRC now owns 1,668 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 1,060 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Vericel during the second quarter worth $73,000. State of Wyoming grew its position in Vericel by 23.8% during the fourth quarter. State of Wyoming now owns 3,025 shares of the biotechnology company's stock valued at $80,000 after buying an additional 581 shares during the period. Finally, Captrust Financial Advisors grew its position in Vericel by 50.8% during the second quarter. Captrust Financial Advisors now owns 3,486 shares of the biotechnology company's stock valued at $88,000 after buying an additional 1,175 shares during the period.

Vericel Stock Up 1.7 %

NASDAQ:VCEL traded up $0.80 on Monday, hitting $48.70. The stock had a trading volume of 352,368 shares, compared to its average volume of 564,772. The company has a fifty day moving average price of $47.57 and a two-hundred day moving average price of $40.13. Vericel Co. has a 1-year low of $29.24 and a 1-year high of $53.05. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of -541.05 and a beta of 1.71.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings data on Thursday, February 29th. The biotechnology company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.18 by $0.08. Vericel had a negative net margin of 1.61% and a negative return on equity of 1.55%. The firm had revenue of $65.00 million for the quarter, compared to analyst estimates of $64.28 million. During the same period in the prior year, the business posted $0.12 EPS. The business's revenue for the quarter was up 23.3% compared to the same quarter last year. As a group, analysts anticipate that Vericel Co. will post 0.09 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. HC Wainwright boosted their target price on shares of Vericel from $46.00 to $53.00 and gave the stock a "buy" rating in a research note on Friday, March 1st. Truist Financial reaffirmed a "buy" rating and set a $54.00 price objective on shares of Vericel in a research note on Tuesday, March 26th. Finally, TheStreet raised shares of Vericel from a "d+" rating to a "c-" rating in a research note on Monday, January 29th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Vericel currently has a consensus rating of "Moderate Buy" and a consensus price target of $46.40.

Insider Transactions at Vericel

In other Vericel news, CEO Dominick Colangelo sold 16,726 shares of the stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $38.58, for a total transaction of $645,289.08. Following the sale, the chief executive officer now directly owns 169,985 shares in the company, valued at approximately $6,558,021.30. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, CEO Dominick Colangelo sold 16,726 shares of the stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $38.58, for a total value of $645,289.08. Following the transaction, the chief executive officer now directly owns 169,985 shares of the company's stock, valued at approximately $6,558,021.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert L. Md Zerbe sold 8,000 shares of the stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $41.85, for a total transaction of $334,800.00. Following the completion of the transaction, the director now directly owns 25,895 shares in the company, valued at $1,083,705.75. The disclosure for this sale can be found here. In the last three months, insiders have sold 63,993 shares of company stock worth $2,761,270. 7.20% of the stock is currently owned by insiders.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.